EC Healthcare provided preliminary unaudited group sales guidance for the six months ended September 30, 2021. For the period, the group expects overall sales volume of no less than HKD 1,520 million representing an increase of no less than 60% as compared with the same period last year and an increase of no less than 43% as compared with the same period in 2019. The board believes that such increase was mainly due to strong demand on medical services offered by the group in conjunction with the rising COVID-19 vaccination rate in Hong Kong; improving local consumption sentiment and a full-fledged recovery of the retail sector as a result of the pandemic remains well under control as well as the launch of consumption voucher scheme by the Hong Kong Government; and positive synergies arisen from the acquisition of medical assets in the second half of the last financial year.